Company news

Relmada Therapeutics, Inc. news in 2023

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023

Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023

November 2, 2023

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

September 19, 2023

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

August 22, 2023

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 7, 2023

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

July 31, 2023

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

March 22, 2023

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023

March 16, 2023

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

January 11, 2023

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

January 8, 2023

Calls in 2023

Decks in 2023